Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib in Chinese Adult Patients With MET Exon 14 Skipping Mutated Advanced NSCLC
NCT04677595Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started May 2021; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04677595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677595.